Fortrea Holdings Inc.

corporate_fare Company Profile

Fortrea Holdings Inc.

FTRE·NASDAQ·Industrial Applications And Services·CIK 0001965040

Fortrea Holdings Inc. is a global contract research organization (CRO) that provides solutions for developing biopharmaceutical products and medical devices. The company serves pharmaceutical, biotechnology, and medical device customers. Fortrea offers clinical trial management services from Phase I through IV, clinical pharmacology, and consulting services. With over 30 years of experience, Fortrea supports customers across more than 20 therapeutic areas using agile delivery models, including Full Service, Functional Service Provider (FSP), and Hybrid structures. The company has approximately 14,300 employees and operates in approximately 100 countries. Fortrea manages its business as one reporting segment: Clinical Services. Fortrea Holdings Inc. was formed on June 29, 2023, through a spin-off of the CRO business from Labcorp Holdings Inc., becoming a standalone, publicly traded company.

Fortrea Holdings Inc. (NASDAQ:FTRE) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 15 items for FTRE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-10, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for FTRE spans 8-K, 10-Q, DEF 14A, 10-K.

Recent high-impact activity:

Fortrea Reinstates CFO Knoblauch After Settling Non-Compete Lawsuit (2026-09-10)
Fortrea Reinstates CFO Jason Knoblauch After Settling Non-Compete Lawsuit (2026-09-10)
Fortrea to Acquire Early Phase Services from Worldwide Clinical Trials for $45M (2026-09-02)
Fortrea Reports Significant Q2 Operational Turnaround with Reduced Net Loss and Positive Cash Flow, Amidst Ongoing CFO Legal Battle (2026-07-29)
Fortrea Q2 Revenue Beats by $30M, Full-Year Guidance Raised (2026-07-29)

Financial Snapshot

Fiscal year ended December 31, 2025

Revenue

$2.72B

Net Income

-$986.2M

Diluted EPS

-$10.81

Op. Cash Flow

$113.5M

Free Cash Flow

$88.3M

Operating Income

-$872.6M

Cash & Equivalents

$174.6M

Total Debt

$1.05B

Debt / Equity

1.87×

Net Margin

-36.2%

Shares Outstanding

93.1M sh

Source: 10-K · filed 2026-02-26 · accession 0001628280-26-012244

Browse all tickers starting with F →

show_chartPrice Chart

Loading chart...

feed FTRE - Latest Insights

Filing Type

Date Range

FTRE

Sep 10, 2026, 8:12 AM EDT

Source: Dow Jones Newswires

Importance Score:

Fortrea Reinstates CFO Knoblauch After Settling Non-Compete Lawsuit

Price at Filing: $16.79

Real-time Price: $17.20

Change: +$0.410 (+2%)

Market Cap: $1.636B

Sentiment: Positive

View Wiseek Article

FTRE

Sep 10, 2026, 7:00 AM EDT

Filing Type: 8-K

Importance Score:

Fortrea Reinstates CFO Jason Knoblauch After Settling Non-Compete Lawsuit

Price at Filing: $16.79

Real-time Price: $17.20

Change: +$0.410 (+2%)

Market Cap: $1.636B

Sentiment: Positive

View Wiseek Article

FTRE

Sep 02, 2026, 7:00 AM EDT

Source: GlobeNewswire

Importance Score:

Fortrea to Acquire Early Phase Services from Worldwide Clinical Trials for $45M

Price at Filing: $17.72

Real-time Price: $17.20

Change: -$0.520 (-3%)

Market Cap: $1.636B

Sentiment: Positive

View Wiseek Article

FTRE

Jul 29, 2026, 4:03 PM EDT

Filing Type: 10-Q

Importance Score:

Fortrea Reports Significant Q2 Operational Turnaround with Reduced Net Loss and Positive Cash Flow, Amidst Ongoing CFO Legal Battle

Price at Filing: $20.40

Real-time Price: $17.20

Change: -$3.20 (-16%)

Market Cap: $1.636B

Sentiment: Neutral

View Wiseek Article

FTRE

Jul 29, 2026, 6:38 AM EDT

Source: Reuters

Importance Score:

Fortrea Q2 Revenue Beats by $30M, Full-Year Guidance Raised

Price at Filing: $20.66

Real-time Price: $17.20

Change: -$3.46 (-17%)

Market Cap: $1.636B

Sentiment: Positive

View Wiseek Article

FTRE

Jul 29, 2026, 6:36 AM EDT

Filing Type: 8-K

Importance Score:

Court Order Sidelines Fortrea's New CFO; Board Director Steps In as Interim While Guidance Is Lifted

Price at Filing: $20.66

Real-time Price: $17.20

Change: -$3.46 (-17%)

Market Cap: $1.636B

Sentiment: Negative

View Wiseek Article

FTRE

Jul 14, 2026, 4:05 PM EDT

Filing Type: 8-K

Importance Score:

Fortrea Loses CAO as CFO Transition Terms Finalized — $1M Severance Package

Price at Filing: $18.03

Real-time Price: $17.20

Change: -$0.830 (-5%)

Market Cap: $1.636B

Sentiment: Negative

View Wiseek Article

FTRE

Jun 26, 2026, 4:42 PM EDT

Filing Type: 8-K

Importance Score:

Fortrea Appoints Jason Knoblauch as New CFO, Reaffirms 2026 Guidance

Price at Filing: $17.65

Real-time Price: $17.20

Change: -$0.450 (-3%)

Market Cap: $1.636B

Sentiment: Neutral

View Wiseek Article

FTRE

Jun 26, 2026, 7:32 AM EDT

Source: Dow Jones Newswires

Importance Score:

Fortrea Holdings Announces CFO Departure, Successor Named for July

Price at Filing: $17.35

Real-time Price: $17.20

Change: -$0.150 (-0.86%)

Market Cap: $1.636B

Sentiment: Neutral

View Wiseek Article

FTRE

May 05, 2026, 4:06 PM EDT

Filing Type: 10-Q

Importance Score:

Fortrea Holdings Reports Substantial Reduction in Q1 Net Loss and Improved Operating Cash Flow

Price at Filing: $14.08

Real-time Price: $17.20

Change: +$3.12 (+22%)

Market Cap: $1.636B

Sentiment: Positive

View Wiseek Article

FTRE

May 05, 2026, 6:13 AM EDT

Source: Wiseek News

Importance Score:

Fortrea Reports Q1 Revenue of $636.5M, Adjusted EPS $0.16; Reaffirms Full-Year Guidance

Price at Filing: $12.26

Real-time Price: $17.20

Change: +$4.94 (+40%)

Market Cap: $1.636B

Sentiment: Neutral

View Wiseek Article

FTRE

May 05, 2026, 6:12 AM EDT

Filing Type: 8-K

Importance Score:

Fortrea Reports Strong Q1 Adjusted Profitability, Affirms Full-Year Guidance with Robust Book-to-Bill

Price at Filing: $12.26

Real-time Price: $17.20

Change: +$4.94 (+40%)

Market Cap: $1.636B

Sentiment: Positive

View Wiseek Article

FTRE

Apr 27, 2026, 6:11 AM EDT

Filing Type: DEF 14A

Importance Score:

Fortrea Schedules Annual Meeting, Details Executive Compensation and New Performance Share Program

Price at Filing: $9.81

Real-time Price: $17.20

Change: +$7.39 (+75%)

Market Cap: $1.636B

Sentiment: Neutral

View Wiseek Article

FTRE

Feb 26, 2026, 4:04 PM EST

Filing Type: 10-K

Importance Score:

Fortrea Reports $986M Net Loss for 2025 Driven by $798M Goodwill Impairment

Price at Filing: $10.80

Real-time Price: $17.20

Change: +$6.40 (+59%)

Market Cap: $1.636B

Sentiment: Negative

View Wiseek Article

FTRE

Feb 26, 2026, 6:05 AM EST

Filing Type: 8-K

Importance Score:

Fortrea Reports Significant Goodwill Impairment and Lower 2026 Revenue Guidance

Price at Filing: $9.90

Real-time Price: $17.20

Change: +$7.30 (+74%)

Market Cap: $1.636B

Sentiment: Negative

View Wiseek Article

Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets

corporate_fare Company Profile